Ist eine Delegation ärztlicher Leistungen auf rheumatologische Fachassistenten bei der Evaluierung von Patienten mit Verdacht auf ankylosierende Spondylitis möglich? – Ergebnisse d...

por Kiltz, U., Spiller, I., Sieper, J., Braun, J.
Publicado 2020

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

por Baraliakos, X, Brandt, J, Listing, J, Sieper, J, Braun, J
Publicado 2005

T cell response in Shigella-induced reactive arthritis

por Brandt, H, Stelzl, U, Kuon, W, Adam, T, Nierhaus, KH, Sieper, J
Publicado 2004

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

por Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, J, Braun, J
Publicado 2005

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab

por Baraliakos, X, Listing, J, Rudwaleit, M, Brandt, J, Sieper, J, Braun, J
Publicado 2005

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis

por Baraliakos, X, Brandt, J, Listing, J, Haibel, H, Rudwaleit, HM, Sieper, J, Braun, J
Publicado 2005

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

por Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., Landewé, R.
Publicado 2015

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

por Marzo‐Ortega, H., Sieper, J., Kivitz, A., Blanco, R., Cohen, M., Martin, R., Readie, A., Richards, H. B., Porter, B.
Publicado 2017

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFA...

por Sieper, J, Lenaerts, J, Wollenhaupt, J, Rudwaleit, M, Mazurov, V I, Myasoutova, L, Park, S, Song, Y, Yao, R, Chitkara, D, Vastesaeger, N
Publicado 2014

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-u...

por Sieper, J, Lenaerts, J, Wollenhaupt, J, Rudwaleit, M, Mazurov, V I, Myasoutova, L, Park, S, Song, Y, Yao, R, Chitkara, D, Vastesaeger, N
Publicado 2014

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: resul...

por Song, I-H, Hermann, K G, Haibel, H, Althoff, C E, Poddubnyy, D, Listing, J, Weiß, A, Freundlich, B, Rudwaleit, M, Sieper, J
Publicado 2011

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled t...

por Song, I-H, Hermann, KG, Haibel, H, Althoff, CE, Listing, J, Burmester, GR, Krause, A, Bohl-Bühler, M, Freundlich, B, Rudwaleit, M, Sieper, J
Publicado 2011

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

por Rudwaleit, M., Rosenbaum, J. T., Landewé, R., Marzo‐Ortega, H., Sieper, J., van der Heijde, D., Davies, O., Bartz, H., Hoepken, B., Nurminen, T., Deodhar, A.
Publicado 2016

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

por van der Heijde, D, Schiff, M H, Sieper, J, Kivitz, A J, Wong, R L, Kupper, H, Dijkmans, B A C, Mease, P J, Davis, J C
Publicado 2008

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis

por Sieper, J., van der Heijde, D., Dougados, M., Maksymowych, W. P., Scott, B. B., Boice, J. A., Berd, Y., Bergman, G., Curtis, S., Tzontcheva, A., Huyck, S., Weng, H. H.
Publicado 2015

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

por Sieper, J, Landewé, R, Rudwaleit, M, van der Heijde, D, Dougados, M, Mease, P J, Braun, J, Deodhar, A, Kivitz, A, Walsh, J, Hoepken, B, Nurminen, T, Maksymowych, W P
Publicado 2015

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

por Braun, J., Haibel, H., de Hooge, M., Landewé, R., Rudwaleit, M., Fox, T., Readie, A., Richards, H. B., Porter, B., Martin, R., Poddubnyy, D., Sieper, J., van der Heijde, D.
Publicado 2019

Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists

por Gossec, L, Dougados, M, Phillips, C, Hammoudeh, M, de Vlam, K, Pavelka, K, Pham, T, Braun, J, Sieper, J, Olivieri, I, van der Heijde, D, Collantes, E, Stone, M, Kvien, T K
Publicado 2008

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction

por Baraliakos, X, Heldmann, F, van den Bosch, F, Burmester, G, Gaston, H, van der Horst-Bruinsma, I E, Krause, A, Schmidt, R, Schneider, M, Sieper, J, Andermann, B, van Tubergen, A, Witt, M, Braun, J
Publicado 2016

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Ph...

por Landewé, R, Braun, J, Deodhar, A, Dougados, M, Maksymowych, W P, Mease, P J, Reveille, J D, Rudwaleit, M, van der Heijde, D, Stach, C, Hoepken, B, Fichtner, A, Coteur, G, de Longueville, M, Sieper, J
Publicado 2014